Temocillin susceptibility in Enterobacterales with an ESBL/AmpC phenotype
<p>Carbapenems are considered the drugs of choice for first-line treatment of severe infections caused by carbapenem-susceptible<b>, </b>extended-spectrum β-lactamases (ESBL)-producing Enterobacterales, while piperacillin-tazobactam has been recommended as an alternative for treatment of non-severe infections. Temocillin is <em>stable to ESBL and AmpC enzymes</em> and may thus represent another treatment option<em>. </em><span>This study assessed the <i>in vitro</i> activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin (3GC)-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>, </span><span>as compared to </span><span>3GC-susceptible isolates of either species</span><span>.</span></p> <p>One hundred and nine isolates from hospitalised patients with bloodstream and urinary tract infections were tested. All isolates were collected during the<span> resistance surveillance study of the Paul-Ehrlich-Society for Chemotherapy in</span> 2016/17. Minimum inhibitory concentrations (MICs) were determined by broth microdilution according to the standard ISO 20776-1 and interpreted using EUCAST clinical breakpoints (version 11.0).</p> <p>Seventy-nine isolates (<i>E. coli</i>, n = 58; <i>K. pneumoniae</i>, n = 21) were 3GC-resistant and 30 (<i>E. coli</i>, n = 15; <i>K. pneumoniae</i>, n = 15) were 3GC-susceptible. Susceptibility to piperacillin-tazobactam was detected in 93.7 % of 3GC-susceptible isolates (for both <i>E. coli</i> and <i>K. pneumoniae</i>) and in 79.3 % and 57.1 % of the 3GC-resistant <i>E. coli</i> and <i>K. pneumoniae</i>, respectively. In contrast, 3GC-susceptible isolates were 100% susceptible to temocillin as were 94.8% and 90.5% of the 3GC-resistant <i>E. coli</i> and <i>K. pneumoniae</i>, respectively.</p> <p>In conclusion, temocillin demonstrated potent <i>in vitro</i> activity against carbapenem-susceptible, 3GC-resistant <i>E. coli</i> and <i>K. pneumoniae</i> from bloodstream and urinary tract infection samples, with susceptibility rates exceeding those of piperacillin-tazobactam.</p>
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 4
- Harmonization
- 12
- Access
- 12
- Reuse readiness
- 0
- Engagement
- 8
Dataset details
- Repository
- dryad
- Published
- May 19, 2022
- License
- cc-zero
- DOI
- 10.5061/dryad.931zcrjkc
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.